Spots Global Cancer Trial Database for Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Official Title: A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma
Study ID: NCT04919642
Interventions
Study Description
Brief Summary: This study is an open-label, multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced cholangiocarcinoma.
Detailed Description: This is a Phase II, open-label study to evaluate the efficacy and safety of TT00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA) with 1) FGFR 2 fusions who failed prior FGFR inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment, 3) with other FGFR alterations, or 4) whose tumors do not contain a detectable FGFR alteration.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Providence Cancer Center, Anchorage, Alaska, United States
City of Hope, Duarte, California, United States
University of California, Los Angeles, School of Medicine, Santa Monica, California, United States
USO Oncology Network- Rocky Mountain Cancer Centers, Denver, Colorado, United States
Mount Sinai Medical Center, Miami Beach, Florida, United States
University of Chicago Medical Center - Duchossis Center for Advanced Medicine, Chicago, Illinois, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Henry Ford Health Center, Detroit, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States
Summit Medical Group - Florham Park Campus, Florham Park, New Jersey, United States
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Stony Brook University - Long Island Cancer Center, Stony Brook, New York, United States
University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
USO Oncology Network-Northwest Cancer Specialists, P.C., Portland, Oregon, United States
Medical College of South Carolina, Charleston, South Carolina, United States
The University of Tennessee Medical Center, Knoxville, Tennessee, United States
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
Methodist Dallas Medical Center, Dallas, Texas, United States
Parkland Health & Hospital System, Dallas, Texas, United States
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States
UT MD Anderson Cancer Center, Houston, Texas, United States
USO Oncology Network-Texas Oncology, Tyler, Texas, United States
USO Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk, Norfolk, Virginia, United States
USO Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke, Virginia, United States
University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact Details
Name: Milind Javle, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
